Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xu Chao

Showing results (171-180 of 281) with videos related to

Pageof 29
Sort By:
Thoracic Cancer|December 4, 2019
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinomaKai Yin, Hui-Bo Feng, Lin-Lin Li, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2014
Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitorZhu Zeng, Hong-hong Yan, Xu-chao Zhang, et al.
Journal of Hematology & Oncology|September 14, 2016
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trialQing Zhou, Jin-Ji Yang, Zhi-Hong Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2014
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805)Qing Zhou, Cai-cun Zhou, Gong-yan Chen, et al.
Annals of Surgical Oncology|December 5, 2012
KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapyJi-lin Guan, Wen-zhao Zhong, She-juan An, et al.
Biomarker Research|July 2, 2020
Clinical characteristics and prognostic value of the <i>KRAS G12C</i> mutation in Chinese non-small cell lung cancer patientsSi-Yang Liu, Hao Sun, Jia-Ying Zhou, et al.
Clinical Lung Cancer|July 22, 2014
Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancerYan-yan He, Xu-chao Zhang, Jin-ji Yang, et al.
Chinese Journal of Cancer|June 29, 2017
Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patientsHao-Ran Zhai, Xue-Ning Yang, Qiang Nie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLCSi-Yang Liu, Lan-Ying Gou, An-Na Li, et al.
Medical Oncology (Northwood, London, England)|April 5, 2011
Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapyShe-Juan An, Yi-Sheng Huang, Zhi-Hong Chen, et al.
Pageof 29

Showing results (171-180 of 281) with videos related to

Sort By:
Pageof 29
Thoracic Cancer|December 4, 2019
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinomaKai Yin, Hui-Bo Feng, Lin-Lin Li, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2014
Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitorZhu Zeng, Hong-hong Yan, Xu-chao Zhang, et al.
Journal of Hematology & Oncology|September 14, 2016
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trialQing Zhou, Jin-Ji Yang, Zhi-Hong Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2014
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805)Qing Zhou, Cai-cun Zhou, Gong-yan Chen, et al.
Annals of Surgical Oncology|December 5, 2012
KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapyJi-lin Guan, Wen-zhao Zhong, She-juan An, et al.
Biomarker Research|July 2, 2020
Clinical characteristics and prognostic value of the <i>KRAS G12C</i> mutation in Chinese non-small cell lung cancer patientsSi-Yang Liu, Hao Sun, Jia-Ying Zhou, et al.
Clinical Lung Cancer|July 22, 2014
Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancerYan-yan He, Xu-chao Zhang, Jin-ji Yang, et al.
Chinese Journal of Cancer|June 29, 2017
Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patientsHao-Ran Zhai, Xue-Ning Yang, Qiang Nie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLCSi-Yang Liu, Lan-Ying Gou, An-Na Li, et al.
Medical Oncology (Northwood, London, England)|April 5, 2011
Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapyShe-Juan An, Yi-Sheng Huang, Zhi-Hong Chen, et al.
Pageof 29